Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

by Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello
Published 2020-11-01